Immunomodulatory properties of anticancer monoclonal antibodies: Is the 'magic bullet' still a reliable paradigm?

Immunotherapy

Volumn 3, Issue 1, 2011, Pages 1-4

  Correale, Pierpaolo ^a   Cusi, Maria Grazia ^b   Tagliaferri, Pierosandro ^c  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

biological response; cancer immunity; modifier; molecular target therapy; monoclonal antibodies

Indexed keywords

BEVACIZUMAB; CETUXIMAB; ERLOTINIB; MONOCLONAL ANTIBODY; PANITUMUMAB;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOMODULATION; NEOPLASMS;

EID: 78650566517     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.92     Document Type: Review

References (19)

1. Ehrlich P: The Collected Papers of Paul Ehrlich. Himmelweit F (Ed.). Pergamon, London, UK (1960).
2. Strebhardt K, Ullrich PAU: Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Can. 8, 473-480 (2008). (Pubitemid 351752547)
3. Weiner LM, Surana R, Wang S: Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10, 317-327 (2010).
4. Campoli M, Ferris R, Ferrone S, Wang X: Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin. Cancer Res. 16, 11-20 (2010).
5. Ross JS, Torres-Mora J, Wagle N, Jennings TA, Jones DM: Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am. J. Clin. Pathol. 134, 478-490 (2010).
6. Saif MW: Colorectal cancer in review: the role of the EGFR pathway. Exp. Opin. Investig. Drugs 19, 357-369 (2010).
7. Ferris RL, Jaffee EM, Ferrone S: Tumor antigen-targeted, monoclonal antibody based immunotherapy: clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 28, 1-10 (2010).
8. von Minckwitz G, du Bois A, Schmidt M et al.: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J. Clin. Oncol. 27, 1999-2006 (2009).
9. Alfaro C, Suarez N, Gonzalez A et al.: Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br. J. Cancer 100, 1111-1119 (2009).
10. Osada T, Chong G, Tansik R et al.: The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57, 1115-1124 (2008).
11. Wang SY, Weiner G: Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin. Biol. Ther. 8, 759-768 (2008). (Pubitemid 351860205)
12. Abès R, Dutertre CA, Agnelli L, Teillaud JL: Activating and inhibitory Fcg receptors in immunotherapy: being the actor or being the target. Expert Rev. Clin. Immunol. 5, 735-747 (2009).
13. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY: Optimizing engagement of the immunesystem by antitumor antibodies: an engineer's perspective. Drug Discov. Today 12, 898-910 (2007).
14. Clynes R: Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol. Oncol. Clin. North Am. 20, 585-612 (2006). (Pubitemid 43817439)
15. Kalergis AM, Ravetch JV: Inducing tumor immunity through the selective engagement of activating Fcg receptors on dendritic cells. J. Exp. Med. 195, 1653-1659 (2002).
16. Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP: Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J. Immunol. 181, 8120-8132 (2008).
17. Galizia G, Lieto E, De Vita F et al.: Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 26, 3654-3660 (2007). (Pubitemid 46842715)
18. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW: Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest 115, 2914-2923 (2005). (Pubitemid 41434419)
19. Zhang CY, Booth JW: Divergent intracellular sorting of Fcg RIIA and Fcg RIIB2. J. Biol. Chem 285(44), 34250-34258 (2010).